x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DPP-001188
| Product Overview | |
|---|---|
| Species | Human |
| Expression System | HEK 293 cells |
| Endotoxin Level | < 1.000 Eu/µg |
| Format | Lyophilized |
| Purity | ≥ 95% by SDS-PAGE |
| Nature | Recombinant |
| Target Information | |
|---|---|
| Gene Name | IL5RA |
| UniProt No. | Q01344 |
| Gene ID | 3568 |
| Molecular Weight | 38 kDa including tags |
| Alternative Names | CD125; CD125 antigen; CDw125; HSIL5R3; IL-5 receptor subunit alpha; IL-5R subunit alpha; IL-5R-alpha; IL-5RA; IL5R; IL5RA; IL5RA_HUMAN; Interleukin 5 Receptor alpha; Interleukin 5 Receptor alpha chain; Interleukin 5 receptor alpha subunit; Interleukin 5 receptor subunit alpha; Interleukin 5 receptor type 3; Interleukin-5 receptor subunit alpha; MGC26560 |
| Function | This is the receptor for interleukin-5. The alpha chain binds to IL5. |
| Cellular Localization | Membrane. |
| Protein Length | Protein fragment |
| Sequence | DLLPDEKISLLPPVNFTIKVTGLAQVLLQWKPNPDQEQRNVNLEYQVKIN APKEDDYETRITESKCVTILHKGFSASVRTILQNDHSLLASSWASAELHA PPGSPGTSIVNLTCTTNTTEDNYSRLRSYQVSLHCTWLVGTDAPEDTQYF LYYRYGSWTEECQEYSKDTLGRNIACWFPRTFILSKGRDWLAVLVNGSSK HSAIRPFDQLFALHAIDQINPPLNVTAEIEGTRLSIQWEKPVSAFPIHCF DYEVKIHNTRNGYLQIEKLMTNAFISIIDDLSKYDVQVRAAVSSMCREAG LWSEWSQPIYVGNDE,Belongs to the type I cytokine receptor family. Type 5 subfamily. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped on dry ice. |
| Storage | Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
